All Studies Meta Analysis Recent:

Ivermectin Use Associated with Reduced Duration of Covid-19 Febrile Illness in a Community Setting

Ghauri et al., International Journal of Clinical Studies & Medical Case Reports, doi:10.46998/IJCMCR.2021.13.000320 (date from preprint)

Dec 2020

Post
Facebook

Source PDF All Meta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020

^*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.

Lower risk for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,000+ studies for 60+ treatments. c19ivm.org

Retrospective 95 outpatients in Pakistan with strong clinical suspicion of COVID-19 (testing was not widely available), with 40 patients treated with ivermectin, showing significantly shorter duration of febrile illness with treatment. Most patients also received HCQ, AZ, zinc, and aspirin. Authors note that there was a treatment delay-response relationship.

This is the 26th of 102 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 560 quintillion).

49 studies are RCTs, which show efficacy with p=0.00000038.

Important missing comments or errors? Let us know.

risk of fever, 92.2% lower, RR 0.08, p = 0.04, treatment 0 of 37 (0.0%), control 7 of 53 (13.2%), NNT 7.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.

risk of fever, 86.4% lower, RR 0.14, p < 0.001, treatment 2 of 37 (5.4%), control 21 of 53 (39.6%), NNT 2.9, day 10.

risk of fever, 55.7% lower, RR 0.44, p < 0.001, treatment 13 of 37 (35.1%), control 42 of 53 (79.2%), NNT 2.3, day 7.

risk of fever, 42.2% lower, RR 0.58, p < 0.001, treatment 21 of 37 (56.8%), control 52 of 53 (98.1%), NNT 2.4, day 5.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Ghauri et al., 15 Dec 2020, retrospective, Pakistan, peer-reviewed, 6 authors, dosage 12mg days 1-6.

This Paper Ivermectin All

Ivermectin Use Associated with Reduced Duration of Covid-19 Febrile Illness in a Community Setting

Muhammad Ishaq Ghauri2, Ali Nasir, Muslim Afsar1, Abbas1, Shariq Muhammad, Mukarram2, Yahya Muhammad, Khizra Ishaq1 Peracha1, Ishaq1, Muhammad Shariq Mukarram, Muhammad Abbas1, Shariq Mukarram, Iver

International Journal of Clinical Studies and Medical Case Reports, doi:10.46998/ijcmcr.2021.13.000320

Background: SARS-CoV-2 infection (COVID-19) is a potentially lethal disease that may progress into severe respiratory distress syndrome requiring ventilatory support. While azithromycin (AZI) and hydroxychloroquine (HCQ) are considered similar to placebo in COVID-19, other drugs such as ivermectin (IVER), are being repurposed to treat this pandemic. This study was designed to assess the effects of ivermectin on duration of febrile illness and disease outcomes in mild-to-moderate COVID-19 infection in a community setting. Methods: In this case-control study 95 suspected patients of mild-to-moderate COVID-19 were included. The controls (Group-A) received AZI+HCQ for seven days while the cases (Group-B) received IVER+AZI+HCQ for six days. Results: A total of 41 patients were in Group-B, while 54 patients were in Group-A. Group-B had consistently and significantly shorter span of fever on days 5, 7, 10 and 14, where the logistic regression showed IVER as the major (Exp B 49•55; p<0•001) underlying factor. The Kaplan-Meier survival analysis showed that Group-A had a prolonged febrile illness (p<0•001). Conclusions: Ivermectin use is associated with reduced duration of febrile illness in COVID-19 in outpatient setting, thus potentially saving precious lives, reducing direct load on healthcare facilities and preventing high cost of management in a community setting.

Supplementary Table: Logistic Regression Analysis Conflict of Interest The authors state that there is no financial or any other conflict of interest in relation to this research. Authors' Contribution NAA and MIG contributed equally. Both contributed in study design, data analysis, writing up the manuscript, overall supervision at their participating institutions respectively, and final approval. MA contributed in data entry and manuscript writing. MSM contributed in data collection and manuscript writing. MYP contributed in data entry and manuscript writing. KI contributed in data collection.

References

Afsar, The looming pandemic of COVID-19: What therapeutic options do we have now?, J Chin Med Assoc, doi:10.1097/JCMA.0000000000000310

Anser, Yousaf, Khan, Social and administrative issues related to the COVID-19 pandemic in Pakistan: better late than never, Environ Sci Pollut Res Int, doi:10.1007/s11356-020-10008-7

Atif, Malik, Why is Pakistan vulnerable to COVID-19 associated morbidity and mortality? A scoping review, Int J Health Plann Manage, doi:10.1002/hpm.3016

Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antivi-ral.2020.104787

Cavalcanti, Zampieri, Rosa, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Engl J Med, doi:10.1056/NE-JMoa2019014

Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot, doi:10.1038/ja.2017.11

Gabler, Keller, Prescriptions Surged as Trump Praised Drugs in Coronavirus Fight, NY Times

Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot, doi:10.1038/s41429-020-0336-z

Hozhabri, Sparascio, Sohrabi, The Global Emergency of Novel Coronavirus (SARS-CoV-2): An Update of the Current Status and Forecasting, Int J Environ Res Public Health, doi:10.3390/ijerph17165648

Hung, Lung, Tso, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, doi:10.1016/S0140-6736(20)31042-4

Kelleni, Nitazoxanide/azithromycin combination for COV-ID-19: A suggested new protocol for early management, Pharmacol Res, doi:10.1016/j.phrs.2020.104874

Kucirka, Lauer, Laeyendecker, Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure, Ann Intern Med, doi:10.7326/M20-1495

Laing, Devaney, Ivermectin -Old Drug, New Tricks?, Trends Parasitol, doi:10.1016/j.pt.2017.02.004

Li, Zhao, Zhan, Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment, J Cell Physiol, doi:10.1002/jcp.30055

Mahévas, Tran, Roumier, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844

Malik, Ishraquzzaman, Kalimuddin, Clinical Presentation, Management and In-Hospital Outcome of Healthcare Personnel With COVID-19 Disease, Cureus, doi:10.7759/cureus.10004

Molina, Delaugerre, Goff, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med Mal Infect, doi:10.1016/j.medmal.2020.03.006

Muñoz, Ballester, Antonijoan, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers, PLoS Negl Trop Dis, doi:10.1371/journal.pntd.0006020

Pandey, Nikam, Shreya, Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements, Life Sci, doi:10.1016/j.lfs.2020.117883

Patrì, Fabbrocini, Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.04.017

Rajter, Sherman, Fatteh, Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study), Chest, doi:10.1016/j.chest.2020.10.009

Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn Schmiedebergs Arch Pharmacol, doi:10.1007/s00210-020-01902-5

Savarino, Trani, Donatelli, Design and derivatives with antimalarial and antiviral activities, Infect Dis, doi:10.1021/jm0601856

Sciama, Is France's president fueling the hype over an unproven coronavirus treatment?, Science

Stokes, Zambrano, Anderson, Coronavirus Disease 2019 Case Surveillance -United States, January 22, Morb Mortal Wkly Rep, doi:10.15585/mmwr.mm6924e2

Tang, Cao, Han, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1136/bmj.m1849

Udugama, Kadhiresan, Kozlowski, Diagnosing COVID-19: The Disease and Tools for Detection, ACS Nano, doi:10.1021/acsnano.0c02624

Wamae, Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-0295

Worldometers, Info, None

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0